Preventive Application of House Dust Mite‐Sublingual Immunotherapy Induces Blocking Antibodies in Sensitized Preschool Children
Open Access
Abstract
Background: Sublingual allergen immunotherapy (SLIT) is an effective treatment for immunoglobulin (Ig)E‐mediated allergies. Its success is associated with allergen‐specific (s)IgG, which blocks IgE‐mediated mechanisms. Preventive effects of SLIT in children before allergy‐symptom onset remain largely unexplored. Methods: A randomized trial was conducted between October 06, 2017 and December 15, 2022, which included house dust mite (HDM)‐sensitized preschool children (aged 3–5 years) showing no allergy symptoms. They were randomized (2:2 blocks) to HDM‐SLIT (300 index of reactivity/day, Staloral) or placebo solution for 2 years. Children receiving > 4 months of treatment were included in the analysis. Primary objective of the study was to compare the groups for change in major HDM allergen‐Der p 1‐sIgG levels from baseline to end of treatment (EOT). Secondary objectives were to compare longitudinal changes (at 4 and 12 months, and EOT) in the (i) levels of HDM‐sIgG subclasses and ‐sIgE using ImmunoCAP/‐ISAC and/or ELISA (ii) Der p‐reactivity in skin and basophils using skin prick test and basophil activation test (BAT), (iii) sensitization status defined as sIgE‐positivity in skin and/or serum, and (iv) Der p‐sIgE‐blocking activity using inhibition‐BAT. Results: Eighteen children received HDM‐SLIT (mean age = 4.26 ± 0.37 years, eight females) and 15 placebo (mean age = 4.16 ± 0.59 years, nine females). HDM‐SLIT increased Der p 1‐sIgG levels between baseline and EOT versus placebo (effect size = 3.11 [95% CL 1.36–4.82], p = 0.001). Additional changes induced by HDM‐SLIT were: increased levels of HDM‐sIgG 1 and ‐sIgG 4 , no long‐term increase in HDM‐sIgE levels, reduced Der p‐reactivity in skin and basophils ( p values ≤ 0.05), and blunted development of new sensitizations. Sera from HDM‐SLIT treated individuals displayed blocking activity on basophils ( p values ≤ 0.05). Conclusions: Preventive application of HDM‐SLIT in allergy‐prone children induces immunomodulatory effects early during treatment (elevated sIgG levels with blocking activity and reduced effector cell responses), thereby revealing potential to interfere with allergy development. Trial Registration: EudraCT#2016‐002844‐18Keywords
Funding Information
- Austrian Science Fund (F4615‐B19)
- Austrian Science Fund (P32953)
- Austrian Science Fund (I4437)
- Gesellschaft für Forschungsförderung Niederösterreich (Danube Allergy Research Cluster (DARC) 1.0)
This publication has 48 references indexed in Scilit:
- Does allergen immunotherapy for allergic rhinitis prevent asthma?Annals of Allergy, Asthma & Immunology, 2022
- A 300 IR sublingual tablet is an effective, safe treatment for house dust mite–induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trialJournal of Allergy and Clinical Immunology, 2021
- IgE-blocking antibodies following SLIT with recombinant Mal d 1 accord with improved apple allergyJournal of Allergy and Clinical Immunology, 2020
- Primary prevention of asthma in high-risk children using HDM SLIT: Assessment at age 6 yearsJournal of Allergy and Clinical Immunology, 2020
- Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergyJournal of Allergy and Clinical Immunology, 2018
- Advances and highlights in allergen immunotherapy: On the way to sustained clinical and immunologic toleranceJournal of Allergy and Clinical Immunology, 2017
- Basic science for the clinician: Mechanisms of sublingual and subcutaneous immunotherapyAnnals of Allergy, Asthma & Immunology, 2016
- Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhoodJournal of Allergy and Clinical Immunology, 2015
- Prophylactic use of sublingual allergen immunotherapy in high-risk children: A pilot studyJournal of Allergy and Clinical Immunology, 2013
- Sublingual immunotherapy induces IL-10–producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviationJournal of Allergy and Clinical Immunology, 2007